Selexipag
Also known as Uptravi (us)
Selexipag is used in adults to treat pulmonary arterial hypertension (PAH, high blood pressure in the vessels that carry blood to the lungs) to slow down the worsening of symptoms and reduce the chance of being hospitalized for PAH.
SMILES: CC(C)N(CCCCOCC(=O)NS(=O)(=O)C)C1=CN=C(C(=N1)C2=CC=CC=C2)C3=CC=CC=C3
Based on 30 units per month. US $354.19 vs India $1.71 per unit.
The savings here are large enough that a trip may still come out ahead. Adjust the numbers to your own situation — every value is an editable estimate.
- Medicine savings over 6 months
- $63,446
- Estimated travel cost
- − $2,300
- Net savings after travel
- $61,146
Even after travel, you could come out ahead by about $61,146.
Assumptions: medicine savings = (US − India monthly price) × months. Travel cost = flights + hotel × nights + buffer. Excludes consultation fees, visas, and other costs. For information only — not medical, legal, or travel advice.
Selexipag is filled about 39.4K times a year under Medicare Part D. At the prices above, that works out to roughly:
Rough estimate. Based on Medicare Part D prescription volume (not the entire US market) scaled by the representative monthly price — actual totals depend on dose, duration and coverage.